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The amino acid sequence of the acrosin-trypsin inhibitor HUSI-II from human seminal plasma is presented which unequivocally identifies HUSI-II 
as being of Kazal-type. In addition, the HUSI-II sequence shows a striking similarity to the middle part of glycoprotein hormone p-subunits thus 
revealing a hitherto unknown structural and evolutionary relationship between Kazal-type inhibitors and glycoprotein hormones. 
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1. INTRODUCTION 
Kazal-type inhibitors are proteinaceous inhibitors of 
serine proteinases with amino acid sequences similar to 
the sequence of bovine pancreatic secretory trypsin in-
hibitor first described by Kazal et al. [1]. Inhibitors of 
Kazal-type have been detected in all vertebrates in-
vestigated. They are present in eggs of birds and amphi-
bians and in many tissues and body fluids such as blood 
plasma, seminal plasma, seminal vesicles, pancreas, 
pancreatic juice, submandibular gland and saliva [2,3). 
The only inhibitor of human origin which was proven 
by sequence comparison as being of Kazal-type is the 
pancreatic secretory trypsin inhibitor [4]. Another tryp-
sin inhibitor, the trypsin-acrosin inhibitor HUSI-II 
from human seminal plasma [5-8] has been suspected 
to be of Kazal-type like the inhibitors found in seminal 
fluids of boar [9] and buH [10,11]. The final proof, 
however, the elucidation of the amino acid sequence of 
HUSI-II, has never been brought forth. We now report 
the amino acid sequence of HUSI-II which une-
quivocally identifies this polypeptide as a Kazal-type in-
hibitor. 
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2. EXPERIMENTAL 
The acrosin-trypsin inhibitor HUSI-II was isolated from a pool of 
human semina! plasma basically as described [6-8]. In brief: after 
centrifugation the cell-free human seminal plasma was ineubated with 
SP-Sephadex C-50 at low ionic strength at pH 5.4. The ion exchanger 
was washed and eluted in a column with a linear gradient of 0-1.0 M 
NaCI in 0.05 M ammonium acetate buffer, pH 5.4. Trypsin inhibitors 
were isolated from the eluate by affinity chromatography on im-
mobilized trypsin and subsequently separated by gel filtration into 
two fractions, HUSI-I (now designated MPI [12]) and HUSI-II. The 
HUSI-II preparation was separated by ion exchange chromatography 
on SP-Sephadex C-25 (sodium phosphate of ionic strength 0.01 and 
pH 6.1-7.3 in 0.19 molll NaCl) into at least 7 peaks of very similar, 
though not eompletely identical amino acid compositions. The two 
prevalent of these chromatographie forms, HUSI-II-5 and -6, were 
used for sequencing. Further purification of these forms and isolation 
of peptides obtained after reduction and carboxymethylation or treat-
ment with pyroglutamyl peptidase [13] was achieved by reversed 
'phase HPLC (butyl or octadecyl column, gradient of acetonitrile in 
O.IOJo trifluoroacetic acid). N-terminal pyroglutamic acid was re-
moved from redueed, carboxymethylated inhibitor by treatment with 
pyroglutamyl peptidase (Boehringer, Mannheim) [13]. The amino 
acid sequences of purified peptides were determined employing an 
Applied Biosystems model 470A gas-phase sequencer with an on-line 
HPLC 120A system for identifieation of the PTH derivatives. The 
NBRF sequenee data bank (release 15) was searched by using the pro-
gram MICROGENIE, version 5 (Beckman). 
3. RESULTS AND DISCUSSION 
In HUSI-Il-6 the reactive site peptide bond PI-P' I 
[14] (positions 23-24 in Fig. 1) is cleaved, therefore, 
two peptides were separated after reduction and alkyla-
tion. Their sequences correspond to positions 6-23 and 
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Fig. 1. Amino acid sequence of HUSI-II and comparison with the sequences of pancreatic secretory trypsin inhibitors and of seminal plasma 
acrosin-trypsin inhibitors. b-, h-, pPSTI: bovine [22], human [4,23], porcine PSTI [24]; BUSI-I, BUSI-IIA: bull semen inhibitor types I [10] and 
HA [11]; POSI: porcine semen inhibitor [9]. The amino acids which are identical to those of the HUSI-II sequence are shaded. The position of 
the PI residue [14] is marked by an arrow. 
24-61 in Fig. 1. Amino acid analysis of the inhibitor 
fraction HUSI-II-5 revealed that it contained 5 addi-
tional amino acids. The N-terminal amino acid of this 
fraction cannot be detected by automatic Edman 
degradation because it is blocked. After incubation 
with pyroglutamyl peptidase the sequence of the 11 N-
terminal residues (2-12 in Fig. 1) was identified. The 
blocked N-terminus was obviously a pyroglutamyl 
residue most probably derived from an original 
glutaminyl. 
Sequence comparisons clearly demonstrated that 
HUSI-II is a Kazal-type serine proteinase inhibitor (Fig. 
1). The sequence of HUSI-II is more similar to the se-
quences of PSTIs than to those of inhibitors from 
seminal plasma of different species (Fig. 1 and Table I). 
An exception is an inhibitor isolated from guinea pig 
seminal vesicles (paper in preparation; sequence data 
not shown here), the sequence similarity of 50.80/0 to 
this inhibitor is significantly higher than to PSTIs. 
A search for proteins with sequence similarities to 
HUSI-II disclosed a high degree of similarity between 
HUSI-I1 and the glycoprotein hormone ß-subunits (Fig. 
2, Table 11). The family of glycoprotein hormones [15] 
is composed of chorionic gonadotropin, luteinizing 
hormone, follicle-stimulating hormone, and thyroid-
stimulating hormone. Within one species, all glycopro-
tein hormones share a common a-subunit, whereas the 
ß-subunits are similar but not identical and determine 
the biological specificity [15]. 
The sequence similarity of HUSI-I1 to glycoprotein 
hormone ß-subunits, especially to hCGß and hLHß is 
strikingly high. The other known human Kazal-type in-
hibitor, hPSTI, shows a lower, but nevertheless clearly 
recognizable similarity to the ß-subunits which is of 
about the same order of magnitude as that of Kazal-
type inhibitors of different species like the 3 domains of 
chicken ovomucoid (Table 11). Presumably due to this 
lower degree of similarity the structural relationship 
between Kazal-type inhibitors and glycoprotein hor-
mones had not been detected before. 
One sequence segment extending over 7 amino acids 
(Fig. 2, numbers 17-23 in the top line) is absolutely 
identical in HUSI-II, hCGß and hLHß. To our 
knowledge an identical segment of this length has never 
been found before in apparently unrelated proteins. 
The conservation of this 17-23 segment during 
evolution might indicate that this part of the molecule 
plays a functionally important role both in HUSI-II and 
in glycoprotein hormones. In fact, this can be taken for 
granted for HUSI-II since in Kazal-type inhibitors the 
corresponding segment includes the major part of the 
region of primary contact between inhibitor and pro-
teinase in the complex (discussed in detail by Laskowski 
et al. [16]). In addition, the C-terminal Arg of the 
17-23 segment (position 23 in Fig. 2) represents the Pt 
residue [14] of the reactive inhibitor site of HUSI-I1, i. 
e. the residue primarily responsible for the specificity of 
the inhibitor. It has been shown that the side chain of 
the Pt residue is inserted into the specificity pocket of 
the proteinases when complexes with the cognate en-
zymes are formed [17,18]. Though no special function 
has been assigned to the 17-23 segment of the glycopro-
tein hormone ß-subunits it is tempting to speculate that 
this part of the molecule might also be involved in a 
strong protein-protein interaction such as complex for-
mation with either the a-subunit or the receptor. In this 
context it is especially interesting that proteinaceous 
proteinase inhibitors can prevent the binding of hCG to 
receptor [19,20]. This finding might suggest that the 
17-23 segment has a tertiary structure similar to that of 
proteinase inhibitors and is reacting with a binding site 
similar to that of proteinases, or it might directly com-
bi ne with a proteinase necessary for the binding of the 
hormone to the receptor. The involvement of such a 
Table I 
Comparison of the sequences of HUSI-II and various Kazal-type in-
hibitors 
bPSTI hPSTI pPSTI BUSI-I BUSI-IIA POSI 
HUSI-II AA 23 21 20 17 16 15 
6-61 -%-----41-.1---3-7.-5---3-5.-7---30-.-4---28-.6-----2-6.-8--
AA and 0,10: number and percentage of amino acids identical in HUSI-
II and the respective inhibitor. For the calculation of percentage only 
the sequence section common to all inhibitors (6 to 61 of the number-
ing of the top line of Fig. 1) was taken into account 
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••• LPQ-vcTiiDVRFESI~iGVDi:'f-V$FPVALSCRjGP#.RRSTSDCGGPiDHPLTCD ••• 52-110 
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Fig. 2. Comparison of the HUSI-II sequence to parts of the sequences of the human glycoprotein hormone ß-subunits [15). Lowercase bold letters 
in the HUSI-II sequence indicate that the same amino acid is found in at least one of the hormone sequences. The amino acids of the ß-subunit 
sequences which are identical to those of the HUSI-II sequence are shaded. The numbering in the top Hne represents the numbering of HUSI-II, 
the right column gives the residue numbers of the respective sequence. The position of the PI residue [14) is marked by an arrow. 
Table II 
Comparison of sequences of several Kazal-type inhibitors and ß-
subunits of glycoprotein hormones. 
hCGß hLHß hTSHß hFSHß 
52-lll 52-110 47-106 46-105 
HUSI-II AA 17 15 13 7 
6-61 070 30.4 26.8 23.2 12.5 
hPSTI AA 8 8 7 8 
1-56 070 14.3 14.3 12.5 14.3 
OMCHII AA 8 7 5 8 
7-62 070 14.3 12.5 8.9 14.3 
OMCHI2 AA 9 7 5 5 
5-60 070 16.1 12.5 8.9 8.9 
OMCHI3 AA 8 8 8 6 
1-51 070 14.3 14.3 14.3 10.7 
OMCHIl, -2, - 3: first, second and third domain of chicken 
ovomucoid [21); AA, 070: number and percentage of identical amino 
acids (100070 = 56). The numbers below the names indicate which sec-
tions of the protein sequences were compared 
proteinase has been proposed [19]. On the other hand, 
it can be deduced that ß-subunits could act as proteinase 
inhibitors. However, in our preliminary experiments 
with hCGß no inhibitory effect on bovine trypsin could 
be detected (data not shown). Currently we are starting 
experiments to investigate whether HUSI-II can an-
tagonize the binding of hCG to its receptor. 
Acknowledgements: We thank H. Fritz for his stimulating and 
helpful discussions. This work was supported by the Sonder-
forschungsbereich 207 of the Deutsche Forschungsgemeinschaft. 
REFERENCES 
[1) Kaza1, L., Spicer, D.S. and Brahinsky, R.A. (1948) J. Am. 
Chem. Soc. 70, 3034-3040. 
[2) Laskowski, M., Jr. and Kato, I. (1980) Annu. Rev. Biochem. 49, 
593-626. 
224 
[3) Laskowski, M., Jr. (1986) in: Nutritiona1 and Toxicological 
Significance of Enzyme Inhibitors in Foods (Friedman, M. ed.) 
pp. 1-17, Plenum, New York. 
[4) Bartelt, D.C., Shapanka, R. and Greene, L.J. (1977) Arch. 
Biochem. Biophys. 179, 189-199. 
[5) Haendle, H., Fritz, H., Trautschold, I. and Werle, E. (1965) 
Hoppe Seyler's Z. Physiol. Chem. 343, 185-188. 
[6) Fink, E., Jaumann, E., Fritz, H., Ingrisch, H. and Werle, E. 
(1971) Z. Physiol. Chem. 352, 1591-1594. 
[7) Fink, E., Fritz, H., Jaumann, E., Schiessler, H., Förg-Brey, B. 
and Werle, E. (1973) in: Protides of the Bio10gical Fluids, Vol. 
20 (Peeters, H. ed.) pp. 425-431, Pergamon, Oxford. 
[8) Schiessler, H., Fink, E. and Fritz, H. (1976) Methods Enzymol. 
65, 847-859. 
[9) Tschesche, H., Kupfer, S., Klauser, R., Fink, E. and Fritz, H. 
(1976) in: Protides of the Biological Fluids, Vol. 23 (Peeters, H. 
ed.) pp. 255-266, Pergamon, Oxford. 
[10) Meloun, B., Jomikova, V. and Cechova, D. (1983) Coll. Czech. 
Chem. Commun. 48, 2558-2568. 
[ll] Meloun, B., Cechova, D. and Jonakova, V. (1984) Hoppe-
Seyler's Z. Physiol. Chem. 364, 1665-1670. 
[12] Fritz, H. (1988) Biol. Chem. Hoppe-Seyler 369, Suppl., 79-82. 
[13] Podell, D.N. and Abraham, G.N. (1978) Biochem. Biophys. 
Res. Commun. 81, 176-185. 
[14] Schechter, I. and Berger, A. (1967) Biochem. Biophys. Res. 
Commun. 27,157-162. 
[15] Pierce, J.G. and Parson, T.F. (1981) Annu. Rev. Biochem. 50, 
465-495. 
[16] Laskowski, M., Jr., Kato, 1., Ardelt, W., Cook, J., Denton, A., 
Empie, M.W., Kohr, W.J., Park, S.J., Parks, K., Schatzley, 
B.L., Schoenberger, O.L., Tashiro, M., Vichot, G., WhatIey, 
H.E., Wieczorek, A. and Wieczorek, M. (1987) Biochemistry 
25, 202-221. 
[17] Papamokos, E., Weber, E., Bode, W., Huber, R., Empie, 
M.W., Kato, I. and Laskowski, M., Jr. (1982) J. Mol. Biol. 158, 
515-537. 
[18] Bolognesi, M., Gatti, G., Menegatti, E., Guarneri, M., Mar-
quart, M., Papamokos, E. and Huber, R.J. (1982) Mol. Biol. 
162, 839-868. 
[19] Wilks, J.W. and Hui, O.J. (1987) Endocrinology 120, 946-952. 
[20] Willey, K.P. and Leidenberger, F.J. (1989) J. Biol. Chem. 264, 
19716-19729. 
[21] Kato, 1., Schrode, J., Kohr, W.J. and Laskowski, M., Jr. (1987) 
Biochemistry 26, 193-201. 
[22) Greene, L.J. and Bartelt, D.C. (1969) J. Biol. Chem. 244, 
2646-2657. 
[23] Yarnamoto, T., Nakamura, Y., Nishide, J., Emi, M., Ogawa, 
M., Mori, T. and Matsubara, K. (1985) Biochem. Biophys. Res. 
Commun. 132, 605-612. 
[24] Bartelt, D.C. and Greene, L.J. (1971) J. Biol. Chem. 246, 
2218-2229. 
